# Statin Combined With Amlodipine Treats Primary Aldosteronism

Study · id `cardio:ct-nct06523465` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT06523465](<https://clinicaltrials.gov/study/NCT06523465>), retrieved 18 November 2026. No person wrote or checked this page.

Also called: NCT06523465

Browse, organ or system: Blood vessels; Kidneys  
Browse, condition area: High blood pressure  

## In plain language

A phase 4 trial registered on ClinicalTrials.gov. The registry status is active, not recruiting. It plans to enroll 180 participants.

## Technical summary

Registry record NCT06523465. Randomized; no masking; primary purpose treatment. Start 2024-09-10 (actual); primary completion 2026-11-15 (anticipated). Results not posted.

## Key facts

- Design: Interventional study; randomized; no masking; primary purpose treatment
- Phase: Phase 4
- Enrolled: 180 participants (planned count; ClinicalTrials.gov record NCT06523465, source copy `cardio:ctgov-nct06523465-2026-11-16`, retrieved 2026-11-18)
- Started: 2024-09-10 (actual) (ClinicalTrials.gov record NCT06523465, source copy `cardio:ctgov-nct06523465-2026-11-16`, retrieved 2026-11-18)
- Primary completion: 2026-11-15 (anticipated) (ClinicalTrials.gov record NCT06523465, source copy `cardio:ctgov-nct06523465-2026-11-16`, retrieved 2026-11-18)
- Completion: 2026-11-15 (anticipated) (ClinicalTrials.gov record NCT06523465, source copy `cardio:ctgov-nct06523465-2026-11-16`, retrieved 2026-11-18)
- Countries: China (ClinicalTrials.gov record NCT06523465, source copy `cardio:ctgov-nct06523465-2026-11-16`, retrieved 2026-11-18)
- Care setting: Not reported
- Registry status: "ACTIVE\_NOT\_RECRUITING" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct06523465-2026-11-16`, retrieved 2026-11-18)

## The registry's words

- Brief title: Statin Combined With Amlodipine Treats Primary Aldosteronism
- Acronym: STOP-PA
- Condition: Primary Aldosteronism
- Condition: Statin
- Condition: Mineralocorticoid Receptor Antagonist
- Condition: Hypertension
- Intervention (Drug): Simvastatin combined with Amlodipine besylate
- Intervention (Drug): Simvastatin combined with Spironolactone and Amlodipine besylate.
- Intervention (Drug): Amlodipine besylate combined Spironolactone
- Lead sponsor: Third Military Medical University
- Lead sponsor class: OTHER

## Connected pages

- Registry condition terms include this condition: Primary aldosteronism (`cardio:primary-aldosteronism`)
- Registry condition terms include this condition: Hypertension (high blood pressure) (`core:hypertension`)
- Registry lists this organization as the lead sponsor: Third Military Medical University (`cardio:org-third-military-medical-university`)

## Provenance

Content hash: 528568212685033cbf255616d463ad94f5719f040983268646b793d7a41f86f7
Last substantive edit: 2026-11-18
Evidence last checked: Not recorded
